1097: Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A,
Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A,
Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of
unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody
J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005 Oct
15;11(20):7454-61. PubMed PMID: 16243819.


1098: Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Targeting osseous 
metastases: rationale and development of radio-immunotherapy for prostate cancer.
Curr Urol Rep. 2005 May;6(3):163-70. Review. PubMed PMID: 15869719.


1099: Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Targeting osseous 
metastases: rationale and development of radio-immunotherapy for prostate cancer.
Curr Oncol Rep. 2004 May;6(3):222-9. Review. PubMed PMID: 15066234.


1100: Morris MJ, Scher HI. Novel therapies for the treatment of prostate cancer: 
current clinical trials and development strategies. Surg Oncol. 2002
Jun;11(1-2):13-23. Review. PubMed PMID: 12031864.


1101: Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of
prostate carcinoma. Cancer. 2000 Sep 15;89(6):1329-48. Review. PubMed PMID:
11002230.